Addiction and Sleep Disorders.
Level 5 - mechanism / opinion, no new human data
Narrative review without systematic methodology or primary human data
PubMed 33537944 · doi:10.1007/978-3-030-61663-2_12
What was done
This is a narrative review describing the bidirectional neurophysiological relationship between sleep disorders and substance addiction. The authors summarize clinical concepts regarding sleep disorder intervention for addiction prevention and relapse reduction, cannabis effects on sleep and withdrawal, and proposed pharmacological and behavioral therapies.
What was found
The abstract reports no numerical data or quantitative outcomes. It describes qualitatively that cannabis improves sleep onset latency initially but loses efficacy with chronic use, insomnia is a key driver of cannabis relapse during withdrawal, and robust clinical trial data evaluating proposed sleep aids (such as suvorexant, mirtazapine, trazodone, and aerobic exercise) remain lacking.
Why it matters
Targeting sleep disruption across prevention and recovery phases could reduce addiction risk and relapse, though evidence-based treatment regimens require further trial validation.
Limits
This is a narrative overview without systematic review methods, primary human participant data, or quantitative synthesis. No specific sample sizes, effect sizes, or comparative trial results are provided.
Cited by
- supports THC decreases sleep onset latency, increases nocturnal awakenings, suppresses REM sleep, and causes rebound insomnia upon cessation.